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ABSTRAK
Tujuan: mengetahui faktor-faktor yang berhubungan dengan In-Stent Restenosis (ISR) pada pasien pasca 
Percutaneous Coronary Intervention (PCI). Metode: desain penelitian ini ialah potong lintang retrospektif 
dengan menggunakan rekam medik pasien pasca PCI yang menjalani follow-up angiografi antara bulan Januari 
tahun 2009 hingga Maret 2014 di Pelayanan Jantung Terpadu/ RSUPN dr. Cipto Mangunkusumo. In-Stent 
Restenosis dinyatakan apabila diameter stenosis pada saat follow-up angiografi sebesar ≥ 50 persen, baik di 
dalam stent maupun menjulur sejauh lima mm keluar dari ujung proksimal atau distal stent. Hasil: didapat 289 
subyek penelitan yang terdiri atas 133 subyek dengan ISR dan 156 tanpa ISR. Kejadian ISR pasca PCI pada 
penggunaan Bare-Metal Stent (BMS) dan Drug-Eluting Stent (DES) yaitu berturut-turut sebesar 61,3% dan 
40,7%. Tipe stent (OR=4,83; 95% IK 2,51-9,30), panjang stent (OR=3,71; 95% IK 1,99-6,90), lesi di bifurkasi 
(OR=2,43; 95% IK 1,16-5,10), merokok (OR=2,30; 95% IK 1,33-3,99), diameter pembuluh darah (OR=2,18; 
95% IK 1,2-3,73), hipertensi (OR=2,16; 95% IK 1,16-4,04) dan diabetes mellitus (OR=2,14; 95% IK 1,23-3,70) 
merupakan faktor prediksi terjadinya ISR. Kesimpulan: tipe stent, panjang stent, lesi di bifurkasi, merokok, 
diameter pembuluh darah, hipertensi dan DM merupakan faktor-faktor yang berhubungan dengan ISR pada 
pasien pasca PCI.
Kata kunci: bare-metal stent; drug-eluting stent; in-stent restenosis.
ABSTRACT
Aim: to determine factors associated with In-Stent Restenosis (ISR) in patients following Percutaneous 
Coronary Intervention (PCI). Methods: a retrospective cross-sectional study was conducted using secondary 
information from medical records of post-PCI patients who underwent follow-up of angiography PCI between 
January 2009 and March 2014 at The Integrated Cardiovascular Service Unit, Cipto Mangunkusumo Hospital, 
Jakarta. Angiographic ISR was defined when the diameter of stenosis ≥50% at follow-up angiography including 
the diameter inside the stent and diameter with five-mm protrusion out of the proximal and distal ends of the stent. 
Results: there were 289 subjects including 133 subjects with and 156 subjects without ISR. The incidence of ISR 
in patients using of bare-metal stent (BMS) and drug-eluting stent (DES) were 61.3% and 40.7%, respectively. 
Factors associated with ISR are stent-type (OR=4.83, 95% CI 2.51-9.30), stent length (OR=3.71, 95% CI 1.99-
6.90), bifurcation lesions (OR=2.43, 95% CI 1.16-5.10), smoking (OR=2.30, 95% CI 1.33-3.99), vascular diameter 
(OR=2.18, 95% CI 1.2-3.73), hypertension (OR=2.16, 95% CI 1.16-4.04) and diabetes mellitus (OR=2.14, 95% 
CI 1.23-3.70). Conclusion: stent type, stent length, bifurcation lesions, smoking, vascular diameter, hypertension 
and DM are factors associated with ISR in patients following PCI.
Key words: bare-metal stent; drug-eluting stent; in-stent restenosis.
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INTRODUCTION 
Advanced science and knowledge has 
allowed us to perform Percutaneous Coronary 
Intervention (PCI) for complex lesions of 
coronary arterial disease (such as multiple vessel 
and left main disease), which is characterized 
by the increasing number of PCI procedures.1,2 
A statistical report in 2014 about heart disease 
and stroke in the United States demonstrated that 
there is an increasing number of PCI procedures 
in both men and women.3 Moreover, data 
between 2002 and 2005 reported that there is also 
a greater number of coronary revascularization 
using PCI procedures compared to Coronary 
Arterial Bypass Graft.4
The increasing number of PCI procedures 
worldwide indicates that there is an increasing 
use of intracoronary stent covering as many 
as 75 to 80 percent.5 However, the procedure 
of stent deploy during PCI will stimulate the 
growth of Smooth Muscle Cells (SMC).6 The 
smooth muscle cells will then migrate from the 
tunica media to intima. The cells subsequently 
will proliferate and develop the Neo Intimal 
Hyperplasia (NIH), which has important role 
in the development of stenotic lesion.7 The 
excessive NIH growth will lead to In-Stent 
Restenosis (ISR).6,8
The intention of using Drug-Eluting Stent 
(DES) in PCI procedure is to reduce the 
incidence of ISR caused by the use of Bare-
Metal Stent (BMS) and it is demonstrated by the 
increasing number of DES utilization compared 
to the BMS.3,9 However, the incidence of ISR in 
patients following PCI, either using DES or BMS 
remains high.10-12 Therefore, our study was aimed 
to identify factors associated with ISR.
METHODS
The design of our study was retrospective 
cross-sectional using secondary data from 
medical records of post PCI patients who 
underwent follow-up angiography of PCI in the 
period between January 2009 and March 2014 
at The Integrated Cardiovascular Service Unit/ 
National Central General Hospital of dr. Cipto 
Mangunkusumo, Jakarta. Extraction of secondary 
data was performed between November and 
March 2014. The inclusion criteria were post 
PCI patients who had undergone follow-up 
angiography within ≥6 months. The exclusion 
criteria were post-PCI patients without medical 
record data or angiographic documentation.
The dependent variable in our study was ISR 
measured based on the Quantitative Coronary 
Angiography (QCA) evaluation. ISR was defined 
when the diameter of stenosis ≥50% at follow-
up angiography including the diameter inside 
the stent and diameter with five-mm protrusion 
out of the proximal and distal ends of the stent. 
The independent variables in our study were: 
(1) clinical variables such as age, sex, diabetes 
mellitus (DM), hypertension, chronic kidney 
disease (CKD) and smoking; (2) variables on 
lesions including the vascular diameter, the 
Left Anterior Descending (LAD) lesion, ostial 
lesion, chronic total occlusions (CTO) lesion, 
bifurcation lesion, and (3) variables on the 
procedure, i.e. the type of stent, the length of 
stent and maximal balloon pressure. Sample size 
was calculated based on formula of sample size 
for hypothetical study with different proportion 
and two independent populations.
Data analysis was performed using SPSS 
statistical analysis computer software. To 
analyze the correlation between independent and 
dependent variables, which both are categorical 
data, the chi-square statistical test was performed. 
The independent variables, which by bivariat 
analysis had p value <0.25 were included in 
multivariate analysis. To identify factors of 
independent variables associated with ISR, 
a multivariate analysis was performed using 
double logistic regression test. To identify 
independent variables that had some effect on 
dependent variables, the effect was evaluated and 
expressed as Odd Ratio (OR). Our study had been 
approved by the Ethical Committee, Faculty of 
Medicine, University of Indonesia.
RESULTS
There were 289 subjects including 133 
subjects with (46%) and 156 subjects without 
(54%) ISR (Table 1). The incidence of ISR in the 
use of Bare-Metal Stent (BMS) and Drug-Eluting 
Stent (DES) were respectively 61.3% and 40.7%.
Based on bivariate analysis, we found nine 
independent variables with p <0.25 including age, 
Vol 47 • Number 3 • July 2015                        Factors associated with in-stent restenosis in patients following PCI
211
smoking, DM, hypertension, CKD, bifurcation 
lesion, type of stent, length of stent and vascular 
diameter. The independent variables with results 
of bivariate analysis of p <0.25 were included in 
the multivariate analysis (Table 2). The results 
of multivariate analysis using double logistic 
regression test demonstrated that there were 
seven independent variables that had significant 
correlation with ISR (Table 3).
DISCUSSION
There was a greater number of male than 
female subjects. It is consistent with statistical 
report on heart disease and stroke in the United 
States in 2014, which demonstrated that there are 
more male subjects compared to female subjects.3
The time frame for follow-up angiography 
following the PCI in our study, either using 
BMS or DES was 15 months, which was longer 
compared to other studies.13 However, Sukhija 
et al14 also had long time frame for follow-up 
angiography in post-PCI patients with DM, i.e. 
16 months (±2 months).14
Statistical report in 2014 found that there 
is higher utilization of DES for PCI procedures 
compared to the BMS.3 Our study also found 
that the use of DES in PCI procedure was more 
common than BMS.
Statistical report in 2014 found that there 
is higher utilization of DES for PCI procedures 
compared to the BMS.3 Our study also found 
that the use of DES in PCI procedure was more 
common than BMS.
Results of studies conducted by Mohan and 
Dall15 as well as Bo et al16 showed that each 
study found lower incidence of ISR following 
PCI procedure when using DES compared to 
using BMS (7.7% vs. 33% and 23.2% vs. 48.8%, 
respectively). Moreover, in post-PCI patients 
who also had DM, Sukhija et al14 found a high 
incidence of ISR (62%). Results of other studies 
also demonstrated the lower incidence of ISR 
in post-PCI patients when using DES compared 
to BMS.10-12 In our study, ther incidence of ISR 
in post-PCI patients using DES was also found 
lower than those using BMS (40.7% vs. 61.3%) 
(Table 2).
Table 1. Basic characteristics of the subjects (n=289)
Characteristics n (%)
Age (years), median (IQR) 61 (54; 67)
Age ≥60, n (%) 147 (50.9)
Sex Male, n (%) 224 (77.5)
Clinical diagnosis during ISR, n (%)
 - APS 256 (88.6)
 - UAP 23 (8.0)
 - NSTEAMI 6 (2.1)
 - STEAMI 4 (1.4)
Time frame for follow-up angiography 
(months), median (IQR) 15 (11; 21)
 - 6 to 12 114 (39.6)
 - >12 to 24 120 (41.7)
 - >24 54 (18.8)
Smoking, n (%) 166 (57.4)
Diabetes Mellitus, n (%) 110 (38.1)
Hypertension, n (%) 215 (74.4)
CKD, n (%) 93 (32.2)
Site of lesion, n (%)
 - RCA 83 (28.7)
 - LCX 50 (17.3)
 - LAD 150 (51.9)
 - LM 6 (2.1)
Ostial lesion, n (%) 25 (8.7)
CTO lesion, n (%) 18 (6.2)
Bifurcation lesion, n (%) 45 (15.6)
Stent type, n (%)
 - BMS 75 (26.0)
 - DES 214 (74.0)
Stent length (mm), median (IQR) 28 (18; 40.50)
Stent length, n (%)
 - >40 72 (24.9)
 - <40 217 (75.1)
Maximal balloon pressure (atm), 
median (IQR) 16 (12; 16)
Maximal balloon pressure, n (%)
 - <14 80 (27.7)
 - >14 209 (72.3)
Vascular diameter (mm), median (IQR) 2.99  
(2.68; 3.49)
Vascular diameter, n (%)
 - <3 147 (50.9)
 - >3 142 (49.1)
Note: Median (percentile 25; percentile 75) for data without 
normal distribution
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Table 2. Factors associated with in-stent restenosis
Variables With ISR (n=133) Without ISR (n=156) P value OR (95% CI)
Age ≥60, n (%) 59 (40.1) 88 (59.9) 0.054 0.62 (0.39 – 0.98)
Sex Female, n (%) 27 (41.5) 38 (58.5) 0.495 0.79 (0.45 – 1.38)
Smoking, n (%) 88 (53.0) 78 (47) 0.008 1.96 (1.21 – 3.15)
Diabetes mellitus, n (%) 59 (53.6) 51 (46.4) 0.056 1.16 (1.01 – 2.65)
Hypertension, n (%) 106 (49.3) 109 (50.7) 0.076 1.69 (0.98 – 2.91)
CKD, n (%) 36 (38.7) 57 (61.3) 0.112 0.65 (0.39 – 1.07)
LAD lesion, n (%) 65 (43.3) 85 (56.7) 0.404 0.80 (0.50 – 1.27)
Ostial lesion, n (%) 14 (56.0) 11 (44.0) 0.402 1.55 (0.68 – 3.54)
CTO lesion, n (%) 8 (44.4) 10 (55.6) 1.000 0.93 (0.36 – 2.44)
Bifurcation lesion, n (%) 28 (62.2) 17 (37.8) 0.027 2.18 (1.13 – 4.19)
Stent type, n (%)
 - BMS 46 (61.3) 29 (38.7) 0.003 2.32 (1.35 – 3.97)
 - DES 87 (40.7) 127 (59.3)
Stent length (mm), n (%)
 - >40 46 (63.9) 26 (36.1) 0.001 2.64 (1.52 – 4.59)
 - ≤40 87 (40.1) 130 (59.9)
Balloon pressure (atm), n (%)
 - <14 40 (50.0) 40 (50.0) 0.479 1.25 (0.74 – 2.09)
 - ≥14 93 (44.5) 116 (55.5)
Vascular diameter (mm), n (%)
 - < 3 78 (53.1) 69 (46.9) 0.020 1.79 (1.12 – 2.86)
 - ≥ 3 55 (38.7) 87 (61.3)
Table 3. Multivariate analysis on factors associated with 
in-stent restenosis
Variables p OR (95% CI)
Stent type 0.001 4.83 (2.51 – 9.30)
Stent length 0.001 3.71 (1.99 – 6.90)
Bifurcation lesion 0.019 2.43 (1.16 – 5.10)
Smoking 0.003 2.30 (1.33 – 3.99)
Vascular diameter 0.005 2.18 (1.27 – 3.73)
Hypertension 0.016 2.16 (1.16 – 4.04)
DM 0.007 2.14 (1.23 – 3.70)
One of possible reasons for the high ISR 
incidence in our study is increased inflammatory 
response, which is consistent with the results of 
a study conducted by Alwi17 who found high 
inflammatory response in patients with Acute 
Coronary Syndrome/ACS (DM with ACS, 
DM with Coronary Heart Disease/CHD, non-
DM ACS and non-DM CHD) in Indonesian 
population.
The Drug-Eluting Stent has grooves or ridges 
coated with polymers containing antiproliferation 
drugs against SMC on vascular wall; therefore, 
the post-PCI NIH development can be reduced.18 
Mose et al19 and Degertekin et al20 found low 
volume of NIH in post-PCI patients who used 
DES compared to those using BMS. In patients 
with STEAMI who underwent PCI, Giglioli et 
al21 also found low ISR incidence in DES users 
compared to those who used BMS. Cassese et al22 
and Solinas et al23 also found low ISR incidence 
in post-PCI patients using DES. Furthermore, 
in DM patients who underwent PCI, Sukhija 
et al14 and Boyden et al24 demonstrated low 
ISR incidence when using DES. Likewise, our 
study also found that DES utilization in post-
PCI patients is a protective factor against the 
development of ISR.
In post-PCI patients with DES, Hong et al25 
found that stent length (>40 mm) as a predictor 
of ISR development. Cassese et al also found 
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that each 10-mm increase of stent length is a 
predictor of ISR development.22 Furthermore, 
Kang et al8 and Kastrati et al13 found that stent 
length is a predictor of ISR development in post-
PCI patients with DES. Our study also found 
that stent length (>40 mm) is a predictor for 
developing ISR.
In post-PCI patients with BMS, Park and 
Park26 found bifurcation lesion as another 
predictor for developing ISR; while in post-
PCI patients with BMS who had small vascular 
diameter, Lijima et al27 also found that bifurcation 
lesion is a predictor of ISR development. 
Likewise, our study also found bifurcation lesion 
as a predictor for developing ISR.
In DM patients who underwent PCI using 
DES, Hong et al28 found smoking as a predictor 
of ISR development. Moreover, in post-PCI 
patients with BMS, Park and Park26 also found 
smoking as a predictor for developing ISR. Our 
study also found that smoking is a predictor for 
ISR development.
The diameter of coronary blood vessel is 
associated with the incidence of ISR.29 Although 
there was no difference regarding maximal 
balloon pressures during PCI procedure with 
BMS between the group with small and large 
diameter, but Akiyama et al30 found increased 
incidence of ISR in the group with small 
diameter. Similar results are also found by 
Kastrati et al13 and Casssese et al22 who found 
reduced vascular diameter of each 0.5 mm is a 
predictor for ISR development. Our study also 
found that the size of vascular diameter is a 
predictor for developing ISR.
Back et al found that hypertension is an 
important factor for developing restenosis in 
patients following percutaneous transluminal 
coronary angioplasty.31 Moreover, Mohan and 
Dhall15 found a significant correlation between 
hypertension and ISR. Our study also fond that 
hypertension is a predictive factor for developing 
ISR.
The results of serial IVUS study by 
Kornowski et al32 found that the number of 
narrowed minimal lumen diameter and NIH 
growth in post-PCI patients who also suffered 
from DM is higher than those without DM. 
A multi-analysis study about the correlation 
between DM and ISR conducted by Qing et al33 
found that DM is a predictor for developing ISR. 
The results of IVUS study in post-PCI patients 
using DES conducted by Rothera et al34 also 
found DM as a predictor of ISR development. 
Based on results of multivariate analysis in post-
PCI patients with BMS, Park and Park26 found 
that DM is a predictive factor for developing ISR. 
By conducting a multi-analysis study, Cassese et 
al22 found DM as a predictor of ISR development, 
either using BMS, first or second generation 
DES. Likewise, our study also found that DM 
is a predictor of ISR development.
Our study has some limitations such as (1) 
it was an analytical retrospective and single-
centered study; (2) it did not evaluate other factors 
associated with ISR for example the type of DES, 
morphology on type of lesions (according to the 
classification of American Heart Association/
AHA), platelet resistance test or evaluation on 
inflammatory response (including igh-sensitivity 
C Reactive Protein/Hs-CRP). Further studies 
are necessary by implementing (1) prospective 
cohort and multi-centered method and (2) further 
evaluation on other factors associated with ISR 
such as the type of DES, morphology on type 
of lesion (AHA), platelet resistance test and 
evaluation on inflammatory response (Hs-CRP).
CONCLUSION
Stent type, stent length, bifurcation lesions, 
smoking, vascular diameter, hypertension and 
DM are factors associated with ISR in patients 
following PCI.
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